drugset / Trial / NCT02563925
Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if the combination of tremelimumab and durvalumab with brain radiation therapy can help treat this type of breast cancer that has spread to the brain.
Timeline
- Start
- 2015-09-18
- Primary completion
- 2021-07-14
- Completion
- 2021-07-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | — |